Metastatic Colorectal Cancer Therapeutics Market Set to Touch US$ 8.7 Billion by 2030, According to RationalStat Published Report
October 12, 2023 08:00 ET
|
Rationalstat LLC
Wilmington, Delaware, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Global Metastatic Colorectal Cancer Therapeutics Market is estimated at a market value of US$ 5.9 billion in 2023 and is predicted to rise at...
Metastatic Colorectal Cancer Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight
October 06, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Metastatic Colorectal Cancer Pipeline Review | Clinical Trials Analysis Report 2021 | DelveInsight Metastatic Colorectal Cancer Pipeline is...
Processa Set to Join Russell Microcap® Index
June 08, 2021 09:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, June 08, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer
September 10, 2020 07:45 ET
|
HalioDx
Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer Marseille, France, September...
Provectus Announces Presentation of Updated Data from Metastatic Uveal Melanoma Cohort of Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
June 01, 2020 09:00 ET
|
Provectus Biopharmaceuticals Inc.
Treatment refractory, immunologically cold, hepatic tumor type37% reduction and 83% stabilization of treated disease (2D-EASL)Overall survival of 11 months for checkpoint inhibition-naïve patients;...
Provectus Announces Publication of Updated Data from Metastatic Neuroendocrine Phase 1 PV-10® Study at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
June 01, 2020 07:00 ET
|
Provectus Biopharmaceuticals Inc.
Treatment refractory, immunologically cold, hepatic tumor type50% reduction of treated disease; 83% stabilization of overall patient disease (RECIST)Median progression-free survival not reached (by CT...
Cascadian Therapeutics Reports Third Quarter 2017 Financial Results
November 08, 2017 16:01 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended...
Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer
September 27, 2017 07:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA")...